• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Streamex Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    1/27/26 4:54:27 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    false 0001530766 0001530766 2026-01-22 2026-01-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    January 22, 2026

     

    Date of Report (Date of earliest event reported)

     

     

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38659   26-4333375
    (State   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification Number)

     

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida 32792

    (Address of principal executive offices) (Zip code)

     

    (203) 409-5444

    (Registrant’s telephone number, including area code)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   STEX   The NASDAQ Stock Market LLC

     

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On January 22, 2026, Streamex Corp. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Needham & Company, LLC, as representative of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to sell and issue to the Underwriters an aggregate of 11,666,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) in a public offering (the “Offering”). The price to the public in the Offering was $3.00 per Share.

     

    The Offering closed on January 26, 2026. The Offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-276298) (the “Registration Statement”) previously filed with the Securities and Exchange Commission (the “Commission”) on December 28, 2023, as amended on January 5, 2024 and December 9, 2024, and declared effective by the Commission on December 17, 2024, as supplemented by the preliminary prospectus supplement, filed with the Commission on January 22, 2026, and a final prospectus supplement, filed with the Commission on January 26, 2026.

     

    In addition, on January 27, 2026, the Underwriters fully-exercised their over-allotment option, purchasing an additional 1,750,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to the Company from the Offering (including the over-allotment option), before deducting the underwriting commissions and other estimated offering expenses, were $40.25 million. The Company intends to use the net proceeds from the Offering to repay prior indebtedness in accordance with our financing strategy, as further described in the Registration Statement, and for working capital and general corporate purposes.

     

    The Underwriting Agreement contains customary representations, warranties and agreements by the Company (including a lock-up agreement, pursuant to which, subject to specified exceptions, the Company has agreed not to offer or transfer shares of Common Stock during the 60-day period following the date of the Underwriting Agreement), customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”) and termination provisions. In connection with the Offering, the Company’s officers and directors have also entered into lock-up agreements, pursuant to which, subject to specified exceptions, they have agreed not to offer or transfer their shares of Common Stock during the 60-day period following the date of the Underwriting Agreement.

     

    The foregoing descriptions of the material terms of the Offering, the Shares, and the Underwriting Agreement do not purport to be complete and are qualified in their entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Sichenzia Ross Ference Carmel, LLP, securities counsel to the Company, delivered an opinion as to the validity of the Shares, a copy of which is filed as Exhibit 5.1 to this Form 8-K and is incorporated herein by reference.

     

     

     

     

    Item 8.01. Other Events.

     

    On January 22, 2026, the Company issued a press release announcing the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    On January 22, 2026, the Company also issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

     

    On January 26, 2026, the Company issued a press release announcing the closing of the Offering. A copy of the press release is attached as Exhibit 99.3 to this Current Report on Form 8-K and incorporated herein by reference.

     

    On January 27, 2026, the Company issued a press release announcing the closing of its overallotment option to the Offering. A copy of the press release is attached as Exhibit 99.3 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits. The following exhibits are filed with this Form 8-K:

     

    Exhibit No.   Description
         
    1.1†+   Underwriting Agreement, dated as of January 22, 2026, by and among the Company, and Needham & Company.
         
    5.1   Opinion of Sichenzia Ross Ference Carmel LLP.
         
    23.1   Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1).
         
    99.1   Press Release, dated January 22, 2026.
         
    99.2   Press Release, dated January 22, 2026.
         
    99.3   Press Release, dated January 26, 2026.
         
    99.4   Press Release, dated January 27, 2026.
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    + Certain schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will provide a copy of such omitted materials to the Securities and Exchange Commission or its staff upon request.
       
    † Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 27, 2026By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
      Title: Chief Executive Officer

     

     

     

    Get the next $STEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors

    WINTER PARK, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Anthony Marciano, Clinical Professor of Finance at NYU Stern School of Business, to its Board of Directors. In this role, Marciano will bring deep expertise in corporate finance, mergers and acquisitions, and financial markets to strengthen Streamex's governance and strategic capital markets initiatives. He is joining as an independent director. "Anthony is an outstanding addition to our Board. His deep-rooted expertise in institutional finance, combined with a stro

    2/4/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Closing of Underwriters' Over-Allotment Option in Full, Resulting in Gross Proceeds of $40.25 Million

    WINTER PARK, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announced the closing of the sale of 1,750,000 shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters in connection with its previously announced underwritten public offering, including a group of technology and mining thought leaders. Together with the 11,666,667 shares issued on January 26, 2026, the Company has now issued a total of 13,416,667 shares of common stock, for total gross proceeds of $40

    1/27/26 4:04:13 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Closing of $35 Million Public Offering

    WINTER PARK, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announced the closing of its previously announced underwritten public offering, including a group of technology and mining thought leaders. The offering consisted of 11,666,667 shares of common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses were approximately $35,000,001.00. The Company intends to use the net proceeds fro

    1/26/26 4:30:00 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    SEC Filings

    View All

    Streamex Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    8-K - Streamex Corp. (0001530766) (Filer)

    1/27/26 4:54:27 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Streamex Corp. (0001530766) (Filer)

    1/27/26 4:51:15 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Streamex Corp.

    424B5 - Streamex Corp. (0001530766) (Filer)

    1/26/26 10:17:08 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Giustra Frank bought $317,000 worth of shares (100,000 units at $3.17) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/4/26 7:04:10 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $71,910 worth of shares (23,500 units at $3.06) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/3/26 11:32:53 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $9,250 worth of shares (2,500 units at $3.70) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    1/29/26 3:30:48 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Giustra Frank bought $317,000 worth of shares (100,000 units at $3.17) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/4/26 7:04:10 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $71,910 worth of shares (23,500 units at $3.06) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/3/26 11:32:53 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $9,250 worth of shares (2,500 units at $3.70) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    1/29/26 3:30:48 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors

    WINTER PARK, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Anthony Marciano, Clinical Professor of Finance at NYU Stern School of Business, to its Board of Directors. In this role, Marciano will bring deep expertise in corporate finance, mergers and acquisitions, and financial markets to strengthen Streamex's governance and strategic capital markets initiatives. He is joining as an independent director. "Anthony is an outstanding addition to our Board. His deep-rooted expertise in institutional finance, combined with a stro

    2/4/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Joins Solana Policy Institute in the Project Open Coalition to Advance Regulated On-Chain Trading of Real-World Assets, Including GLDY

    LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets, today announced it has joined Project Open, a landmark initiative working to establish a regulated framework for the issuance and trading of securities on public blockchains. The effort aims to unlock billions in traditional asset value through 24/7 trading, instant settlement, lower costs, and enhanced transparency for all real-world assets, while keeping the United States competitive in financial innovation. Streamex joins Solana Policy Institute united to drive the next era of compliant digital market infrastructur

    12/10/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Appointment of Kevin Gopaul, Global Financial Executive and ETF Pioneer to Its Board of Directors

    LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Kevin Gopaul, global financial executive and pioneering leader in the exchange-traded fund (ETF) industry, to its Board of Directors, effective immediately. Kevin brings more than 25 years of global asset management and capital markets experience, including senior leadership roles as Global Head of ETFs, Chief Investment Officer, and Canadian CEO at BMO Global Asset Management, where he helped architect and scale the firm's $100 billion ETF franchise. He currently serves

    11/18/25 8:09:24 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

    LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. ("Empress") (TSXV:EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. ("Terra Capital"), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an

    12/11/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Launch of $100,000,000 USD GLDY Pre-Sale – A Gold-Backed Yield Generating Stablecoin Offering Institutional Yield on Physical Gold Bullion

    The launch of Streamex's $100 million USD GLDY pre-sale marks a historic opportunity for gold investors. Investing in gold is no longer just a static store of value, Streamex, through GLDY has created a yield-generating, institutional grade asset designed to offer both spot gold exposure and yield paid in additional ounces of physical gold bullion.  Key Highlights Gold Price Exposure and Gold-Denominated Distributions: GLDY is designed to combine audited physical bullion holdings with yield from institutionally managed gold leases sourced through Monetary Metals. GLDY seeks to provide exposure to the price of gold while targeting periodic distributions paid in additional ounces of gold.Rev

    11/10/25 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care